STA
RMD icon

Summit Trail Advisors’s ResMed RMD Stock Holding History

Summit Trail Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
8,559
-619
-7% -$128K 0.02% 718
2026
Q1 		$2.06M Buy
9,178
+2,737
+42% +$682K 0.03% 498
2025
Q4 		$1.55M Sell
6,441
-1,528
-19% -$391K 0.03% 562
2025
Q3 		$2.18M Buy
7,969
+1,122
+16% +$306K 0.03% 404
2025
Q2 		$1.77M Buy
+6,847
New +$1.63M 0.03% 295
2024
Q4 		– Sell
-1,497
Closed -$365K – 680
2024
Q3 		$365K Buy
1,497
+202
+16% +$45.1K 0.01% 490
2024
Q2 		$248K Sell
1,295
-8
-0.6% -$1.62K 0.01% 537
2024
Q1 		$258K Buy
1,303
+76
+6% +$13.9K 0.01% 506
2023
Q4 		$211K Sell
1,227
-197
-14% -$30.3K 0.01% 483
2023
Q3 		$211K Buy
1,424
+268
+23% +$48.5K 0.01% 490
2023
Q2 		$253K Buy
+1,156
New +$258K 0.01% 413
2018
Q1 		– Sell
-240
Closed -$24K – 1394
2017
Q4 		$24K Buy
+240
New +$19.8K ﹤0.01% 997

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Summit Trail Advisors's RMD Position: Q2 2026 in Review

Summit Trail Advisors reduced its ResMed (RMD) stake by 6.7% in Q2 2026, selling an estimated $128K and leaving 8,559 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #718.

Summit Trail Advisors first reported a position in RMD in Q4 2017 and has held it in 12 quarters since. The position peaked at $2.18M in Q3 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Summit Trail Advisors held 8,559 shares of ResMed worth $1.67M as of Q2 2026.
  • Summit Trail Advisors sold 619 ResMed shares in Q2 2026, an estimated $128K.
  • ResMed made up 0.02% of Summit Trail Advisors's portfolio in Q2 2026, its #718 holding.
  • Summit Trail Advisors first reported a position in ResMed in Q4 2017 and has held it in 12 quarters since.
  • Summit Trail Advisors's ResMed position peaked at $2.18M in Q3 2025.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.